Kaufer D I, Cummings J L, Christine D
Department of Neurology, University of California at Los Angeles School of Medicine, USA.
J Geriatr Psychiatry Neurol. 1996 Jan;9(1):1-6. doi: 10.1177/089198879600900101.
We conducted an open-label study designed to assess the effects of tacrine on behavioral changes in patients with Alzheimer's disease (AD). Twenty-eight subjects completed a baseline evaluation and at least one assessment during treatment. Behavioral symptoms and cognitive function were assessed with the Neuropsychiatric Inventory (NPI) and Mini-Mental State Examination (MMSE), respectively. The mean NPI score at the maximum individual dose of tacrine attained was markedly decreased (behavior improved, compared to baseline). Symptoms of anxiety, apathy, hallucinations, aberrant motor behaviors, and disinhibition were most responsive. Subject stratification by dementia severity revealed a substantially reduced mean NPI score only in the group with moderate dementia, independent of cognitive response. Over half of the subjects with cognitive improvement had a marked reduction in behavioral symptoms, particularly apathetic behaviors. These data suggest that tacrine may be beneficial for selected behavioral symptoms in AD patients, particularly at higher doses and in those with moderate cognitive deficits.
我们进行了一项开放标签研究，旨在评估他克林对阿尔茨海默病（AD）患者行为变化的影响。28名受试者完成了基线评估，并在治疗期间进行了至少一次评估。分别使用神经精神科问卷（NPI）和简易精神状态检查表（MMSE）对行为症状和认知功能进行评估。在达到他克林的最大个体剂量时，平均NPI评分显著降低（与基线相比，行为改善）。焦虑、冷漠、幻觉、异常运动行为和脱抑制症状反应最为明显。按痴呆严重程度进行的受试者分层显示，仅在中度痴呆组中平均NPI评分大幅降低，与认知反应无关。超过一半认知改善的受试者行为症状显著减轻，尤其是冷漠行为。这些数据表明，他克林可能对AD患者的某些行为症状有益，尤其是在高剂量时以及对那些有中度认知缺陷的患者。
